Small Pharma to Participate in the 34th Annual Roth
Presentation to be webcast on Monday, March 14 at 3:30 – 3:55PM/PT...
Stay updated with breaking news from Peter Rands. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Presentation to be webcast on Monday, March 14 at 3:30 – 3:55PM/PT...
Presentation to be webcast on Monday, March 14 at 3:30 – 3:55PM/PTLONDON, March 09, 2022 -- Small Pharma Inc. , a neuroscience company focused on psychedelic-assisted therapies for mental... | March 9, 2022
Peter Rands, Chief Executive Officer, Small Pharma Inc. ("Small Pharma" or "the Company") (TSXV: DMT), and his team joined Dani Lipkin, Director, Global Business Development TMX Group, to celebrate the Company's new listing on TSX Venture Exchange and open the market.
Small Pharma on conducting world’s first clinical trials for psychedelic DMT and listing in Canada Small Pharma's (CVE:DMT) Peter Rands joins Proactive to introduce his company after launching on Toronto’s TSX Venture Exchange, raising C$58mln to develop medicines based on N,N-Dimethyltryptamine (DMT) to treat depression. The firm is committed to helping accelerate the development of effective therapeutic treatments for mental health disorders. The company is currently conducting the world’s first clinical trials exploring the potential for the psychedelic N, N-Dimethyltryptamine (DMT) ...